What is it about?

IgA nephropathy is most common in people of East Asian ancestry. This analysis showed that, in patients from mainland China who took part in the NefIgArd study, Nefecon (a targeted-release form of the corticosteroid budesonide) was an effective and well-tolerated treatment for IgA nephropathy.

Featured Image

Read the Original

This page is a summary of: Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results, Kidney360, October 2024, Wolters Kluwer Health,
DOI: 10.34067/kid.0000000583.
You can read the full text:

Read

Contributors

Be the first to contribute to this page